{"gene":"IKZF1","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2013,"finding":"Lenalidomide causes selective ubiquitination and proteasomal degradation of IKZF1 (and IKZF3) via the CRBN-CRL4 E3 ubiquitin ligase complex. A single amino acid substitution in IKZF3 conferred resistance to lenalidomide-induced degradation, confirming the mechanism. Lenalidomide-induced IL-2 production in T cells was also attributed to depletion of IKZF1/IKZF3.","method":"Quantitative proteomics, ubiquitination assays, rescue with amino acid substitution mutant, genetic knockdown","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — quantitative proteomics plus mutagenesis rescue, replicated independently in same year by Lu et al. (PMID:24292623)","pmids":["24292625","24292623"],"is_preprint":false},{"year":2013,"finding":"Lenalidomide-bound cereblon E3 ubiquitin ligase acquires the ability to target IKZF1 and IKZF3 for proteasomal degradation. Loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect in myeloma cell lines.","method":"Biochemical binding assays, genetic loss-of-function in myeloma cell lines, proteasomal degradation assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — necessity and sufficiency demonstrated with genetic approaches, independently replicated (PMID:24292625)","pmids":["24292623"],"is_preprint":false},{"year":1994,"finding":"LyF-1 (the lymphocyte-specific DNA-binding protein that activates TdT, lambda5, VpreB, and lck promoters) is encoded by specific alternatively spliced mRNAs from the Ikaros gene. Only isoforms containing the N-terminal zinc finger domain are necessary and sufficient for TdT promoter binding; at least six distinct mRNA isoforms arise from alternative splicing with differing DNA-binding specificities.","method":"Protein purification, partial amino acid sequencing, recombinant protein expression in E. coli, antibody blocking of DNA-binding activity, RT-PCR isoform analysis, gel-shift assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution with recombinant protein plus antibody blocking plus isoform mutagenesis, foundational identity paper","pmids":["7935426"],"is_preprint":false},{"year":1991,"finding":"LyF-1 (IKZF1) is a ~50 kDa sequence-specific DNA-binding protein that interacts with the consensus sequence PyPyTGGGAGPu in the TdT promoter (required for lymphocyte transcription), the immunoglobulin mu enhancer microB element, and promoters of lambda5, VpreB, and lck, identifying it as a general transcriptional activator for lymphocyte-specific genes.","method":"Protein purification, gel-shift (EMSA), transient transfection, promoter mutational analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — purified protein, in vitro DNA-binding assays, functional promoter analysis","pmids":["1922043"],"is_preprint":false},{"year":1995,"finding":"Ikaros acts as a tumor suppressor and regulator of T cell proliferation thresholds; heterozygous mutation in the DNA-binding domain causes T cell hyperproliferation, autoproliferative peripheral T cells, and rapid T cell leukemia/lymphoma with 100% penetrance via clonal expansion and loss of the wild-type allele.","method":"Mouse genetics (heterozygous knock-in of DNA-binding domain mutation), flow cytometry, clonal analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo dominant-negative genetic model with clear phenotypic readout, foundational study","pmids":["7585946"],"is_preprint":false},{"year":2005,"finding":"IKZF1 is SUMOylated in vivo at two identified sites; simultaneous modification of both SUMOylation sites abolishes Ikaros repression function by disrupting both HDAC-dependent and HDAC-independent repression, without affecting nuclear localization to pericentromeric heterochromatin.","method":"In vivo SUMOylation assays, site-directed mutagenesis of SUMOylation sites, HDAC activity assays, nuclear localization imaging","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis of specific SUMOylation sites with functional repression readout, single lab but multiple orthogonal methods","pmids":["15767674"],"is_preprint":false},{"year":2009,"finding":"Ikaros interacts with protein phosphatase 1 (PP1) via a conserved RVXF motif in its C-terminus. PP1 dephosphorylates CK2-phosphorylated sites on Ikaros, stabilizing the protein and enabling pericentromeric heterochromatin (PC-HC) localization and DNA binding. Point mutations abolishing Ikaros-PP1 interaction decrease DNA binding, prevent PC-HC localization, and accelerate proteasomal degradation of Ikaros via the ubiquitin pathway.","method":"Co-immunoprecipitation, RVXF motif mutagenesis, subcellular localization imaging, DNA-binding assays, protein stability (half-life) assays, ubiquitin co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis of PP1-binding motif with multiple functional readouts (localization, DNA binding, stability), single lab, multiple orthogonal methods","pmids":["19282287"],"is_preprint":false},{"year":2011,"finding":"CK2 kinase phosphorylates Ikaros at four specific sites; phosphomimetic mutations at these CK2 sites inhibit Ikaros localization to pericentromeric heterochromatin, reduce DNA binding to target gene promoters (e.g., TdT), and promote proteasomal degradation of Ikaros. Phosphoresistant mutations at CK2 sites restore DNA binding, PC-HC localization, and prevent accelerated degradation.","method":"Ikaros phosphomimetic and phosphoresistant mutants, subcellular localization assays, ChIP, DNA-binding assays, protein stability assays","journal":"Molecular and cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phosphomimetic and phosphoresistant mutagenesis with multiple functional readouts, single lab, multiple orthogonal methods","pmids":["21750978"],"is_preprint":false},{"year":2010,"finding":"Ikaros and Aiolos bind directly to the c-Myc promoter in pre-B cells in vivo and suppress c-Myc expression. Downregulation of c-Myc is necessary for the growth-inhibitory effect of Ikaros/Aiolos, and precedes p27 induction and cyclin D3 downregulation.","method":"ChIP, siRNA knockdown, overexpression, cell proliferation assays, time-course expression analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates direct promoter occupancy, functional rescue/loss experiments, single lab, multiple orthogonal methods","pmids":["20566697"],"is_preprint":false},{"year":2015,"finding":"Ikaros forms a complex with Polycomb Repressive Complex 2 (PRC2) in CD4−CD8− thymocytes, enabling PRC2 binding to >500 developmentally regulated loci including haematopoietic stem cell and Notch pathway genes. Loss of Ikaros in these cells reduces H3K27 trimethylation and causes ectopic gene expression. Ikaros interaction with PRC2 is independent of the NuRD complex.","method":"Conditional genetic inactivation, ChIP-seq, co-immunoprecipitation, H3K27me3 assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus ChIP-seq plus genetic KO with epigenetic readout, single lab, multiple orthogonal methods","pmids":["26549758"],"is_preprint":false},{"year":1999,"finding":"Upon T cell activation, Ikaros proteins localize to a higher-order chromatin structure at pericentromeric heterochromatin where they colocalize with components of the DNA replication machinery. T cells with reduced Ikaros activity show chromosome abnormalities when proliferating, implicating Ikaros in chromosome propagation during cell cycle.","method":"Immunofluorescence/nuclear localization imaging, chromosome analysis in proliferating T cells, TCR and IL-2 signaling assays","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment tied to chromosome phenotype in reduced-Ikaros T cells, single lab, two orthogonal methods","pmids":["10204489"],"is_preprint":false},{"year":2008,"finding":"Endogenous Ikaros is recruited to the human beta-globin locus and targets HDAC1 and Mi-2 to gamma-globin promoters, contributing to gamma-globin gene silencing. Ikaros physically interacts with GATA-1 and enhances GATA-1 binding to regulatory regions, and their combined action impairs proximity between the locus control region and gamma-globin genes.","method":"ChIP, co-immunoprecipitation, reporter assays, chromosome conformation capture (3C)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP, Co-IP, and chromosome conformation capture in primary cells, single lab with multiple orthogonal methods","pmids":["19114560"],"is_preprint":false},{"year":2011,"finding":"Ikaros physically interacts with Cdk9 (a component of P-TEFb) via its N-terminal zinc finger domain and with GATA factors via its C-terminal zinc finger domain. These interactions promote transcription elongation of Ikaros target genes (including gamma-globin) by facilitating Cdk9 and GATA recruitment to promoters and conversion of RNA Pol II to the elongation-competent form. The oncogenic isoform Ik6 fails to interact with Cdk9 or GATA and perturbs Pol II elongation.","method":"Co-immunoprecipitation, domain mapping/mutagenesis, ChIP, in vivo transcription elongation assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — domain mutagenesis plus ChIP plus functional transcription assays, single lab, multiple orthogonal methods","pmids":["21245044"],"is_preprint":false},{"year":2013,"finding":"Direct protein-protein interactions between Ikaros C-terminal zinc fingers and GATA1/GATA2/GATA3 C-terminal zinc fingers, and between Ikaros N-terminal zinc fingers and the kinase/T-loop domain of Cdk9, are required for transcriptional activation of Ikaros target genes in hematopoietic cells. The Ik6 oncogenic isoform does not efficiently interact with Cdk9 or GATA proteins in vivo, perturbing P-TEFb recruitment and transcription elongation.","method":"Co-immunoprecipitation, domain deletion/mutagenesis, ChIP, transcriptional reporter assays in COS-7 and primary hematopoietic cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — detailed domain mutagenesis plus Co-IP plus ChIP, single lab, multiple orthogonal methods","pmids":["23732910"],"is_preprint":false},{"year":2005,"finding":"Reintroduction of Ikaros into Ikaros-null T leukemia cells causes G0/G1 cell cycle arrest with upregulation of p27kip1, induction of T cell differentiation markers, and global and locus-specific increase in histone H3 acetylation, demonstrating Ikaros has tumor suppressor properties in T cells.","method":"Ikaros overexpression in leukemia cell line, flow cytometry (cell cycle), Western blot, immunofluorescence, histone acetylation assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function in defined cell line with multiple phenotypic readouts, single lab","pmids":["15713624"],"is_preprint":false},{"year":2009,"finding":"Ikaros directly occupies the tbx21 (T-bet) promoter in Th2 cells to repress T-bet expression and prevent IFNγ production. Loss of Ikaros DNA-binding in Th2 conditions leads to T-bet expression and IFNγ production. Ikaros is also required for epigenetic imprinting of the ifng locus during Th2 polarization.","method":"ChIP (endogenous Ikaros occupancy), dominant-negative Ikaros inhibition, cytokine production assays, in vivo parasite model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus dominant-negative functional experiment, single lab, two methods","pmids":["19923223"],"is_preprint":false},{"year":2006,"finding":"Disruption of Ikaros in chicken DT40 B cells causes B cell receptor (BCR) signaling defects including reduced PLCγ2 phosphorylation, impaired intracellular calcium mobilization, and hyperphosphorylation of Cbl following BCR activation. These defects are rescued by Ikaros reintroduction.","method":"Gene disruption in DT40 cells, Ikaros reintroduction, phosphorylation assays, calcium mobilization assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic KO with rescue, multiple signaling readouts, single lab","pmids":["16482514"],"is_preprint":false},{"year":2012,"finding":"Ikaros overexpression decreases NOTCH-induced megakaryocytic specification and represses megakaryocytic genes including GATA-1. Combined loss of Ikzf1 and Gata1 produces synthetic lethality in vivo with expansion of megakaryocyte progenitors, demonstrating a functional interplay between Ikaros, GATA factors, and the NOTCH pathway in megakaryopoiesis.","method":"Overexpression, genetic knockout (single and double), in vivo mouse models, flow cytometry","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (synthetic lethality), overexpression studies, single lab","pmids":["23335373"],"is_preprint":false},{"year":2021,"finding":"In myeloid cells, IKZF1 regulates pyroptosis via canonical inflammasome signaling in a SIRT1-dependent manner. Ikaros negatively regulates SIRT1 through an AMPK-dependent pathway. Myeloid-specific Ikaros signaling augments hepatic pyroptosis and pro-inflammatory responses in vivo.","method":"Ikaros silencing/overexpression in BMM cultures, myeloid-specific Sirt1-KO mice, in vivo liver ischemia-reperfusion model, inflammasome signaling assays","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with mechanistic pathway readouts, single lab, multiple in vivo and in vitro models","pmids":["34871625"],"is_preprint":false},{"year":2006,"finding":"Human Ikaros isoforms hIK-VI and hIK-H differ in DNA-binding affinity and subcellular localization: hIK-VI localizes exclusively to pericentromeric heterochromatin (PC-HC) while hIK-H shows dual centromeric and non-centromeric localization. Mutational analysis defined amino acids responsible for hIK-H's distinct DNA binding and localization. Co-expression of hIK-H with hIK-VI alters the DNA-binding specificity of Ikaros complexes toward PC-HC sequences.","method":"Isoform expression, mutational analysis, subcellular localization imaging, DNA-binding assays (EMSA), ChIP","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus localization plus DNA-binding experiments, single lab","pmids":["17135265"],"is_preprint":false},{"year":2020,"finding":"Ikaros antagonizes STAT5 DNA binding in pre-B cells by competing for overlapping GGAA binding motifs at >60% of STAT5 target genomic regions, causing widespread loss of STAT5 chromatin binding within two hours of Ikaros induction. Ikaros does not alter STAT5 protein levels or phosphorylation, nor does it physically associate with STAT5.","method":"ChIP-seq (genomic distribution of Ikaros and STAT5), inducible Ikaros expression system, Western blot, co-immunoprecipitation (negative for STAT5 interaction)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus inducible system showing rapid displacement, single lab, two orthogonal methods","pmids":["33180866"],"is_preprint":false},{"year":2023,"finding":"IKAROS assembles lineage-specific chromatin organization at multiple scales in B cell precursors, including interactions across megabase distances that override CTCF-imposed boundaries and build lineage-specific regulatory units. IKAROS-bound enhancers drive these long-range interactions. Gain-of-function in epithelial cells confirms IKAROS' direct ability to reconfigure chromatin architecture. IKAROS is also required for Igκ locus compaction in lymphocytes.","method":"Loss-of-function (conditional KO in B cell precursors), gain-of-function (ectopic expression in epithelial cells), Hi-C/chromatin conformation capture, ChIP-seq","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — complementary LOF and GOF genetics plus Hi-C chromatin architecture, multiple cell types, rigorous controls","pmids":["37995656"],"is_preprint":false},{"year":2014,"finding":"Ikaros binds to a variant site in the first intron of PP2A and represses PP2A (PP2Ac) expression at the mRNA and protein level. This repression is at least partially dependent on recruitment of HDAC1 to the intronic binding site. Silencing of Ikaros enhances PP2A expression.","method":"ChIP, siRNA knockdown, overexpression, luciferase reporter assays, Western blot, RT-PCR","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP showing occupancy, siRNA bidirectional regulation, single lab, multiple methods","pmids":["24692537"],"is_preprint":false},{"year":2019,"finding":"Ikaros controls B cell receptor anergy by regulating anergy-associated genes including Zfp318 (which promotes IgD expression in anergic B cells). In Ikaros-deficient mature B cells, TLR-MyD88-NF-κB signaling is hyperactive due to failure to upregulate feedback inhibitors. Loss of MyD88 in Ikaros-deficient B cells prevents systemic autoimmunity.","method":"Conditional KO in mature B cells, genetic epistasis (MyD88 deletion), gene expression analysis, BCR/TLR signaling assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO plus epistasis rescue experiment, multiple signaling readouts","pmids":["31591571"],"is_preprint":false},{"year":2018,"finding":"IKZF1 directly regulates CD34+ cell fate by being degraded via CRBN E3 ligase upon IMiD treatment, reducing IKZF1-dependent PU.1 transcription factor expression. ChIP shows IKZF1 directly binds the PU.1 promoter. CRBN knockdown reverses IMiD-induced IKZF1 downregulation. An IKZF1-Q146H mutation blocks CRBN binding and prevents IKZF1 ubiquitination.","method":"ChIP, thalidomide analog bead pull-down, CRBN knockdown (shRNA), IKZF1 Q146H mutant overexpression, colony-formation assays, xenograft model","journal":"Blood advances","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP plus pull-down plus mutagenesis plus knockdown rescue, single lab, multiple orthogonal methods","pmids":["29496670"],"is_preprint":false},{"year":2024,"finding":"IKZF1 directly represses Cish (a negative regulator of IL-15 receptor signaling) in NK cells; Ikzf1-null NK cells have impaired IL-15 receptor signaling and increased BIM-mediated apoptosis. IKZF1 and IKZF3 directly bind AP-1 family members (Jun/Fos); deletion of both Ikzf1 and Ikzf3 in NK cells further reduces Jun/Fos expression and causes complete loss of peripheral NK cells.","method":"Conditional genetic inactivation (Ikzf1 KO, Ikzf1/Ikzf3 double KO, Ikzf1/Bcl2l11 co-deletion), ChIP-seq (direct AP-1 binding), cytokine signaling assays, flow cytometry","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq plus multiple genetic models with epistasis, replicated across conditions","pmids":["38182668"],"is_preprint":false},{"year":2024,"finding":"IKZF1 drives T cell exhaustion via epigenetic modulation; degradation of IKZF1 by iberdomide prevents exhaustion by blocking chromatin remodeling at T cell effector enhancers and preserving binding of AP-1, NF-κB, and NFAT transcription factors.","method":"Antigen-specific T cell exhaustion assay, epigenetic screen, ATAC-seq/chromatin accessibility, iberdomide treatment, transcription factor occupancy assays","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromatin accessibility assays plus TF occupancy analysis with IKZF1 degrader, single lab, multiple methods","pmids":["39486420"],"is_preprint":false},{"year":2019,"finding":"In zebrafish, Ikzf1 directly regulates Ccr9a and Irf4a expression, which are required for thymic migration and T cell differentiation of hematopoietic stem/progenitor cells respectively. Restoration of ccr9a in ikzf1 mutants rescues thymic homing but not T cell differentiation; additional irf4a restoration rescues differentiation.","method":"Zebrafish genetic ablation (ikzf1 mutant), genetic rescue (ccr9a and irf4a reintroduction), ChIP/direct target validation, flow cytometry of thymic populations","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in zebrafish ortholog with direct target validation, single lab","pmids":["31511326"],"is_preprint":false},{"year":2021,"finding":"Germline IKZF1 variants affecting the C-terminal dimerization domain disrupt IKZF1 homo- and heterodimerization (completely or partially) without affecting wild-type allele function. These dimerization-defective mutants alter IKZF1 sumoylation, protein stability, and recruitment of the NuRD complex, contrasting with N-terminal DNA-binding defect mutants, which do not affect these mechanisms.","method":"Dimerization assays, sumoylation assays, protein stability assays, NuRD complex co-immunoprecipitation, patient germline variant characterization","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical assays on patient variants, single lab, multiple methods","pmids":["32845957"],"is_preprint":false},{"year":2010,"finding":"Ikaros-1 is expressed at the boundary of the striatal germinal zone/mantle zone during neurogenesis, where it induces cell cycle arrest of neural progenitors by upregulating p21Cip1/Waf1 and promotes differentiation of enkephalin-positive neurons. Ikaros-1 acts downstream of Dlx1/2 transcription factors in the striatum.","method":"Ikaros-KO mouse analysis, overexpression in primary striatal cultures, Dlx1/2 double-KO analysis, immunohistochemistry","journal":"The Journal of comparative neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus overexpression plus epistasis (Dlx1/2 double KO), single lab","pmids":["19950118"],"is_preprint":false},{"year":2024,"finding":"A germline IKZF1 variant in IgG4-RD patients increases binding to the FYN promoter, resulting in higher FYN transcription in T cells. Elevated FYN stabilizes JunB and biases T cells toward Th2 polarization. This mechanistic chain accounts for atopic/autoimmune manifestations linked to IKZF1 risk variants.","method":"Functional characterization of patient germline variant, promoter binding assay (increased FYN binding), T cell differentiation assays, T cell receptor transduction assay","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding assay plus functional T cell differentiation, single lab/family study","pmids":["38885295"],"is_preprint":false},{"year":2025,"finding":"IKAROS regulates surface expression of CD19 and CD22 in a dose-dependent and reversible manner in B-ALL cells. IKAROSlow B-ALL cells undergo epigenetic and transcriptional changes reducing B-cell identity, which leads to reduced CD19 and CD22 surface expression and resistance to CAR T cell therapies.","method":"Single-cell analysis of 61 patient samples, IKAROS dose-dependent overexpression/knockdown experiments, epigenetic assays (ATAC-seq), antigen expression assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dose-dependent manipulation plus epigenetic profiling, single lab, multiple methods","pmids":["40268897"],"is_preprint":false}],"current_model":"IKZF1/IKAROS is a zinc finger transcription factor that binds GGAA-containing DNA motifs (via N-terminal zinc fingers) and dimerizes (via C-terminal zinc fingers), directly activating or repressing target genes in hematopoietic cells; it recruits chromatin-remodeling complexes (NuRD/HDAC, PRC2) and the transcription elongation factor P-TEFb/Cdk9 to regulatory elements, controls pericentromeric heterochromatin localization, interacts with GATA factors, antagonizes STAT5 chromatin binding, assembles lineage-specific 3D genome architecture, and is subject to post-translational regulation by CK2 phosphorylation (which impairs DNA binding and promotes degradation), PP1-mediated dephosphorylation (which stabilizes the protein), and SUMOylation (which blocks repression); additionally, lenalidomide and related IMiD drugs redirect the CRBN-CRL4 E3 ubiquitin ligase to ubiquitinate and proteasomally degrade IKZF1, a mechanism that underlies both the anti-myeloma activity of these drugs and their effects on T cells and innate lymphoid cells."},"narrative":{"mechanistic_narrative":"IKZF1/IKAROS is a lymphocyte-restricted zinc finger transcription factor that programs hematopoietic gene expression by binding GGAA-containing DNA motifs and orchestrating both activation and repression of lineage-specific genes [PMID:1922043, PMID:7935426]. First identified as the DNA-binding protein LyF-1 that engages the TdT, mu enhancer, lambda5, VpreB, and lck promoters, its sequence specificity and dimerization properties are partitioned across distinct zinc finger domains and tuned by extensive alternative splicing into isoforms with differing DNA-binding affinity and pericentromeric heterochromatin localization [PMID:1922043, PMID:7935426, PMID:17135265]. IKAROS executes transcriptional control through partner recruitment: its N-terminal zinc fingers engage Cdk9/P-TEFb to drive RNA Pol II elongation while its C-terminal fingers bind GATA1/2/3, and it additionally recruits HDAC1/Mi-2 (NuRD), PRC2, and assembles long-range, lineage-specific chromatin architecture that overrides CTCF boundaries [PMID:21245044, PMID:23732910, PMID:19114560, PMID:26549758, PMID:37995656]. It directly represses growth and identity genes including c-Myc, T-bet, PP2A, Cish, and the megakaryocytic program, and antagonizes STAT5 by competing for overlapping GGAA sites, thereby setting proliferation thresholds and enforcing lineage choice across B, T, NK, and myeloid cells [PMID:20566697, PMID:19923223, PMID:24692537, PMID:38182668, PMID:33180866, PMID:23335373]. Consistent with this role, IKAROS is a tumor suppressor whose loss or DNA-binding-domain mutation drives T cell hyperproliferation and leukemia [PMID:7585946, PMID:15713624]. IKAROS activity is set by post-translational regulation: CK2 phosphorylation impairs DNA binding and promotes degradation, PP1-mediated dephosphorylation stabilizes the protein and enables heterochromatin localization, and SUMOylation blocks its repressive function [PMID:21750978, PMID:19282287, PMID:15767674]. Lenalidomide and related IMiDs redirect the CRBN-CRL4 E3 ubiquitin ligase to ubiquitinate and degrade IKZF1, the basis of their anti-myeloma activity and of their immunomodulatory effects, with a Q146H substitution conferring degradation resistance [PMID:24292623, PMID:24292625, PMID:29496670]. Germline IKZF1 variants disrupting either dimerization or DNA binding alter NuRD recruitment, stability, and downstream signaling, underlying immune dysregulation phenotypes [PMID:32845957, PMID:38885295].","teleology":[{"year":1991,"claim":"Established the molecular identity of IKAROS as a sequence-specific transcriptional activator, answering what protein controls lymphocyte-specific promoters.","evidence":"Protein purification and EMSA on the TdT, mu enhancer, lambda5, VpreB, and lck promoters","pmids":["1922043"],"confidence":"High","gaps":["Gene/cDNA identity not yet established at this stage","No in vivo loss-of-function"]},{"year":1994,"claim":"Linked LyF-1 DNA-binding activity to the Ikaros gene and showed alternative splicing generates isoforms with distinct DNA-binding specificities, explaining functional diversity from a single locus.","evidence":"Recombinant protein expression, antibody blocking, RT-PCR isoform analysis, gel-shift","pmids":["7935426"],"confidence":"High","gaps":["Functional consequence of each isoform in vivo unresolved","Partner proteins not yet identified"]},{"year":1995,"claim":"Defined IKAROS as a tumor suppressor that sets T cell proliferation thresholds, answering whether IKAROS dysfunction is oncogenic.","evidence":"Mouse heterozygous knock-in of a DNA-binding domain mutation with clonal analysis","pmids":["7585946"],"confidence":"High","gaps":["Direct target genes mediating tumor suppression not defined here","Mechanism of wild-type allele loss unclear"]},{"year":1999,"claim":"Connected IKAROS to higher-order chromatin and chromosome propagation, addressing where in the nucleus IKAROS acts upon T cell activation.","evidence":"Immunofluorescence localization to pericentromeric heterochromatin and chromosome analysis in proliferating T cells","pmids":["10204489"],"confidence":"Medium","gaps":["Molecular basis of heterochromatin targeting not defined","Causal link between localization and chromosome stability correlative"]},{"year":2005,"claim":"Identified SUMOylation as a switch controlling IKAROS repression, answering how repressive activity is post-translationally toggled.","evidence":"In vivo SUMOylation assays, site mutagenesis, HDAC and localization readouts","pmids":["15767674"],"confidence":"High","gaps":["SUMO ligase/protease responsible not identified","Single-lab finding"]},{"year":2006,"claim":"Showed IKAROS controls BCR signaling and that isoforms differ in DNA-binding and subcellular targeting, refining how IKAROS output is diversified.","evidence":"DT40 gene disruption with rescue plus signaling assays; isoform mutational and localization analysis","pmids":["16482514","17135265"],"confidence":"Medium","gaps":["Direct transcriptional targets in BCR pathway not mapped","Isoform stoichiometry in primary cells unknown"]},{"year":2008,"claim":"Defined IKAROS as a recruiter of HDAC1/Mi-2 and a GATA-1 partner that reshapes locus architecture, answering how it silences specific genes.","evidence":"ChIP, Co-IP, reporter assays, and 3C at the human beta-globin locus","pmids":["19114560"],"confidence":"High","gaps":["Generality beyond globin locus not addressed here","Order of complex assembly unresolved"]},{"year":2010,"claim":"Showed IKAROS directly represses c-Myc to inhibit pre-B cell growth, providing a target-level mechanism for its anti-proliferative role.","evidence":"ChIP, siRNA/overexpression, proliferation and time-course expression assays","pmids":["20566697"],"confidence":"High","gaps":["Cofactor requirement at c-Myc promoter not defined","Cell-type generality untested here"]},{"year":2011,"claim":"Established the kinase/phosphatase logic and the P-TEFb/GATA recruitment mechanism, answering how IKAROS activity and activating output are controlled.","evidence":"CK2 phosphomimetic/phosphoresistant mutants and Cdk9/GATA domain-mapping with ChIP and elongation assays","pmids":["21750978","21245044","19282287"],"confidence":"High","gaps":["In vivo phosphorylation dynamics during development unclear","Single-lab mechanistic studies"]},{"year":2013,"claim":"Revealed the IMiD/CRBN degradation mechanism and resolved domain-specific partner contacts, transforming IKAROS into a druggable target and mapping its activation interface.","evidence":"Quantitative proteomics, ubiquitination assays, mutagenesis rescue in myeloma; domain mutagenesis with ChIP for GATA/Cdk9 contacts","pmids":["24292625","24292623","23732910"],"confidence":"High","gaps":["Full set of neosubstrate-determining residues incomplete","Long-range chromatin consequences of degradation not addressed here"]},{"year":2015,"claim":"Demonstrated IKAROS recruits PRC2 to deposit H3K27me3 at developmental loci, adding a Polycomb repression axis distinct from NuRD.","evidence":"Conditional KO, ChIP-seq, Co-IP, and H3K27me3 profiling in thymocytes","pmids":["26549758"],"confidence":"High","gaps":["Recruitment determinants for PRC2 vs NuRD selectivity unknown","Direct vs indirect PRC2 contact not fully resolved"]},{"year":2020,"claim":"Showed IKAROS antagonizes STAT5 by motif competition rather than protein interaction, clarifying a mechanism of signaling cross-regulation.","evidence":"ChIP-seq with inducible IKAROS, Western blot, and negative Co-IP in pre-B cells","pmids":["33180866"],"confidence":"Medium","gaps":["Functional consequences for B cell development not quantified here","Single-lab finding"]},{"year":2023,"claim":"Established IKAROS as a direct architect of lineage-specific 3D genome organization, answering how it imposes regulatory units genome-wide.","evidence":"Conditional KO, ectopic gain-of-function in epithelial cells, Hi-C and ChIP-seq","pmids":["37995656"],"confidence":"High","gaps":["Mechanism of CTCF-boundary override not molecularly defined","Cohesin/loop-extrusion interplay unresolved"]},{"year":2024,"claim":"Extended IKAROS function to NK cell survival, T cell exhaustion, and AP-1 partnership, broadening its lineage roles and therapeutic relevance.","evidence":"Conditional/double-KO genetics with ChIP-seq (NK); ATAC-seq and TF occupancy with IKAROS degrader (T cell exhaustion); patient variant FYN promoter study","pmids":["38182668","39486420","38885295"],"confidence":"Medium","gaps":["Direct vs cofactor-mediated AP-1 binding not fully resolved","Generalizability of exhaustion findings beyond model systems untested"]},{"year":2025,"claim":"Linked IKAROS dosage to B-cell identity antigen expression, explaining a mechanism of resistance to CD19/CD22-directed therapies.","evidence":"Single-cell analysis of patient samples plus dose-dependent manipulation with ATAC-seq","pmids":["40268897"],"confidence":"Medium","gaps":["Direct vs indirect regulation of CD19/CD22 loci not separated","Reversibility kinetics in vivo unknown"]},{"year":null,"claim":"How IKAROS selects between its repressive (NuRD, PRC2, HDAC) and activating (P-TEFb, GATA) partner programs at a given locus, and how this is coordinated with its 3D architecture function, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of partner selection","Recruitment hierarchy at individual loci undefined","Integration of post-translational state with partner choice unmapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,2,19,20]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,8,15,12,13]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,6,7,19]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[10,19,21]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[9,11]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,12,13,8]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[9,11,21]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[23,25,15,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[17,27,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,24,28]}],"complexes":["NuRD","PRC2"],"partners":["GATA1","GATA2","GATA3","CDK9","HDAC1","CRBN","IKZF3","PPP1CA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13422","full_name":"DNA-binding protein Ikaros","aliases":["Ikaros family zinc finger protein 1","Lymphoid transcription factor LyF-1"],"length_aa":519,"mass_kda":57.5,"function":"Transcription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta-globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs) (By similarity). Function is isoform-specific and is modulated by dominant-negative inactive isoforms (PubMed:17135265, PubMed:17934067)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q13422/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IKZF1","classification":"Not Classified","n_dependent_lines":35,"n_total_lines":1208,"dependency_fraction":0.028973509933774833},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IKZF1","total_profiled":1310},"omim":[{"mim_id":"621233","title":"IMMUNODYSREGULATION WITH VARIABLE IMMUNODEFICIENCY AND AUTOIMMUNITY; IMDIA","url":"https://www.omim.org/entry/621233"},{"mim_id":"619437","title":"IMMUNODEFICIENCY 84; IMD84","url":"https://www.omim.org/entry/619437"},{"mim_id":"616873","title":"IMMUNODEFICIENCY, COMMON VARIABLE, 13; CVID13","url":"https://www.omim.org/entry/616873"},{"mim_id":"615002","title":"CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2, BETA; CAMKK2","url":"https://www.omim.org/entry/615002"},{"mim_id":"613067","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC, SUSCEPTIBILITY TO, 2; ALL2","url":"https://www.omim.org/entry/613067"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":160.4},{"tissue":"lymphoid tissue","ntpm":99.0}],"url":"https://www.proteinatlas.org/search/IKZF1"},"hgnc":{"alias_symbol":["hIk-1","LyF-1","Hs.54452","IKAROS","PPP1R92"],"prev_symbol":["ZNFN1A1"]},"alphafold":{"accession":"Q13422","domains":[{"cath_id":"3.30.160.60","chopping":"109-167","consensus_level":"high","plddt":80.1617,"start":109,"end":167},{"cath_id":"3.30.160","chopping":"170-224","consensus_level":"medium","plddt":76.56,"start":170,"end":224},{"cath_id":"3.30.160","chopping":"459-519","consensus_level":"medium","plddt":63.029,"start":459,"end":519}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13422","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13422-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13422-F1-predicted_aligned_error_v6.png","plddt_mean":47.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IKZF1","jax_strain_url":"https://www.jax.org/strain/search?query=IKZF1"},"sequence":{"accession":"Q13422","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13422.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13422/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13422"}},"corpus_meta":[{"pmid":"24292625","id":"PMC_24292625","title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24292625","citation_count":1492,"is_preprint":false},{"pmid":"24292623","id":"PMC_24292623","title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24292623","citation_count":1258,"is_preprint":false},{"pmid":"20428194","id":"PMC_20428194","title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/20428194","citation_count":419,"is_preprint":false},{"pmid":"7585946","id":"PMC_7585946","title":"A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma.","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7585946","citation_count":419,"is_preprint":false},{"pmid":"11913067","id":"PMC_11913067","title":"Haematopoietic cell-fate decisions, chromatin regulation and ikaros.","date":"2002","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11913067","citation_count":256,"is_preprint":false},{"pmid":"9143685","id":"PMC_9143685","title":"The role of the Ikaros gene in lymphocyte development and homeostasis.","date":"1997","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9143685","citation_count":219,"is_preprint":false},{"pmid":"1922043","id":"PMC_1922043","title":"LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1922043","citation_count":206,"is_preprint":false},{"pmid":"7935426","id":"PMC_7935426","title":"The lymphoid transcription factor LyF-1 is encoded by specific, alternatively spliced mRNAs derived from the Ikaros gene.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7935426","citation_count":192,"is_preprint":false},{"pmid":"21477865","id":"PMC_21477865","title":"The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21477865","citation_count":185,"is_preprint":false},{"pmid":"29681510","id":"PMC_29681510","title":"Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29681510","citation_count":169,"is_preprint":false},{"pmid":"26321221","id":"PMC_26321221","title":"Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.","date":"2015","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/26321221","citation_count":155,"is_preprint":false},{"pmid":"10204489","id":"PMC_10204489","title":"Ikaros sets thresholds for T cell activation and regulates chromosome propagation.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10204489","citation_count":137,"is_preprint":false},{"pmid":"11870616","id":"PMC_11870616","title":"Ikaros is critical for B cell differentiation and function.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11870616","citation_count":129,"is_preprint":false},{"pmid":"29519871","id":"PMC_29519871","title":"The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.","date":"2018","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/29519871","citation_count":122,"is_preprint":false},{"pmid":"38301010","id":"PMC_38301010","title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.","date":"2024","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38301010","citation_count":119,"is_preprint":false},{"pmid":"12752680","id":"PMC_12752680","title":"Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies.","date":"2003","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12752680","citation_count":114,"is_preprint":false},{"pmid":"20566697","id":"PMC_20566697","title":"Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20566697","citation_count":106,"is_preprint":false},{"pmid":"29278858","id":"PMC_29278858","title":"The Ikaros family in lymphocyte development.","date":"2017","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29278858","citation_count":103,"is_preprint":false},{"pmid":"34871625","id":"PMC_34871625","title":"Myeloid Ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.","date":"2021","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/34871625","citation_count":97,"is_preprint":false},{"pmid":"15767674","id":"PMC_15767674","title":"Ikaros SUMOylation: switching out of repression.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15767674","citation_count":88,"is_preprint":false},{"pmid":"19282287","id":"PMC_19282287","title":"Ikaros stability and pericentromeric localization are regulated by protein phosphatase 1.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19282287","citation_count":78,"is_preprint":false},{"pmid":"12406904","id":"PMC_12406904","title":"Ikaros regulates neutrophil differentiation.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12406904","citation_count":76,"is_preprint":false},{"pmid":"31151137","id":"PMC_31151137","title":"Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation.","date":"2019","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31151137","citation_count":76,"is_preprint":false},{"pmid":"29588478","id":"PMC_29588478","title":"Ikaros family zinc finger 1 regulates dendritic cell development and function in humans.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29588478","citation_count":72,"is_preprint":false},{"pmid":"11997672","id":"PMC_11997672","title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation.","date":"2002","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/11997672","citation_count":68,"is_preprint":false},{"pmid":"26549758","id":"PMC_26549758","title":"Ikaros mediates gene silencing in T cells through Polycomb repressive complex 2.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26549758","citation_count":67,"is_preprint":false},{"pmid":"25085254","id":"PMC_25085254","title":"Ikaros fingers on lymphocyte differentiation.","date":"2014","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25085254","citation_count":65,"is_preprint":false},{"pmid":"25753742","id":"PMC_25753742","title":"Ikaros and leukaemia.","date":"2015","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/25753742","citation_count":64,"is_preprint":false},{"pmid":"31591571","id":"PMC_31591571","title":"Ikaros prevents autoimmunity by controlling anergy and Toll-like receptor signaling in B cells.","date":"2019","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31591571","citation_count":63,"is_preprint":false},{"pmid":"8474456","id":"PMC_8474456","title":"Both LyF-1 and an Ets protein interact with a critical promoter element in the murine terminal transferase gene.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8474456","citation_count":59,"is_preprint":false},{"pmid":"19114560","id":"PMC_19114560","title":"Ikaros and GATA-1 combinatorial effect is required for silencing of human gamma-globin genes.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19114560","citation_count":58,"is_preprint":false},{"pmid":"15713624","id":"PMC_15713624","title":"Ikaros induces quiescence and T-cell differentiation in a leukemia cell line.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15713624","citation_count":58,"is_preprint":false},{"pmid":"22778136","id":"PMC_22778136","title":"GATA-1 utilizes Ikaros and polycomb repressive complex 2 to suppress Hes1 and to promote erythropoiesis.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22778136","citation_count":54,"is_preprint":false},{"pmid":"17307348","id":"PMC_17307348","title":"Ikaros and chromatin regulation in early hematopoiesis.","date":"2007","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17307348","citation_count":53,"is_preprint":false},{"pmid":"19923223","id":"PMC_19923223","title":"Ikaros silences T-bet expression and interferon-gamma production during T helper 2 differentiation.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19923223","citation_count":53,"is_preprint":false},{"pmid":"28385788","id":"PMC_28385788","title":"The making of a lymphocyte: the choice among disparate cell fates and the IKAROS enigma.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/28385788","citation_count":52,"is_preprint":false},{"pmid":"22150303","id":"PMC_22150303","title":"Ikaros and tumor suppression in acute lymphoblastic leukemia.","date":"2011","source":"Critical reviews in oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22150303","citation_count":51,"is_preprint":false},{"pmid":"27818917","id":"PMC_27818917","title":"The Ikaros family of zinc-finger proteins.","date":"2016","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/27818917","citation_count":51,"is_preprint":false},{"pmid":"20888815","id":"PMC_20888815","title":"Ikaros in immune receptor signaling, lymphocyte differentiation, and function.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20888815","citation_count":50,"is_preprint":false},{"pmid":"32245541","id":"PMC_32245541","title":"IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly.","date":"2020","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32245541","citation_count":50,"is_preprint":false},{"pmid":"21750978","id":"PMC_21750978","title":"Ikaros, CK2 kinase, and the road to leukemia.","date":"2011","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21750978","citation_count":49,"is_preprint":false},{"pmid":"23335373","id":"PMC_23335373","title":"Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23335373","citation_count":49,"is_preprint":false},{"pmid":"36433803","id":"PMC_36433803","title":"Inborn errors of human IKAROS: LOF and GOF variants associated with primary immunodeficiency.","date":"2023","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36433803","citation_count":48,"is_preprint":false},{"pmid":"32845957","id":"PMC_32845957","title":"Germline IKAROS dimerization haploinsufficiency causes hematologic cytopenias and malignancies.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32845957","citation_count":48,"is_preprint":false},{"pmid":"33563611","id":"PMC_33563611","title":"The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.","date":"2021","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/33563611","citation_count":43,"is_preprint":false},{"pmid":"20299195","id":"PMC_20299195","title":"Awakening lineage potential by Ikaros-mediated transcriptional priming.","date":"2010","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20299195","citation_count":42,"is_preprint":false},{"pmid":"17135265","id":"PMC_17135265","title":"Human Ikaros function in activated T cells is regulated by coordinated expression of its largest isoforms.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17135265","citation_count":41,"is_preprint":false},{"pmid":"35525905","id":"PMC_35525905","title":"Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35525905","citation_count":41,"is_preprint":false},{"pmid":"29705243","id":"PMC_29705243","title":"A kindred with mutant IKAROS and autoimmunity.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29705243","citation_count":39,"is_preprint":false},{"pmid":"37995656","id":"PMC_37995656","title":"Lineage-specific 3D genome organization is assembled at multiple scales by IKAROS.","date":"2023","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/37995656","citation_count":38,"is_preprint":false},{"pmid":"33331000","id":"PMC_33331000","title":"Established and emergent roles for Ikaros transcription factors in lymphoid cell development and function.","date":"2020","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33331000","citation_count":37,"is_preprint":false},{"pmid":"33499314","id":"PMC_33499314","title":"Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33499314","citation_count":37,"is_preprint":false},{"pmid":"27865806","id":"PMC_27865806","title":"Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.","date":"2016","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/27865806","citation_count":35,"is_preprint":false},{"pmid":"27666503","id":"PMC_27666503","title":"Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.","date":"2016","source":"Advances in biological regulation","url":"https://pubmed.ncbi.nlm.nih.gov/27666503","citation_count":33,"is_preprint":false},{"pmid":"9618757","id":"PMC_9618757","title":"Ikaros in hemopoietic lineage determination and homeostasis.","date":"1998","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9618757","citation_count":33,"is_preprint":false},{"pmid":"16482514","id":"PMC_16482514","title":"Ikaros has a crucial role in regulation of B cell receptor signaling.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16482514","citation_count":33,"is_preprint":false},{"pmid":"36970148","id":"PMC_36970148","title":"Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.","date":"2023","source":"RSC medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36970148","citation_count":32,"is_preprint":false},{"pmid":"19950118","id":"PMC_19950118","title":"Ikaros-1 couples cell cycle arrest of late striatal precursors with neurogenesis of enkephalinergic neurons.","date":"2010","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19950118","citation_count":32,"is_preprint":false},{"pmid":"34936696","id":"PMC_34936696","title":"Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34936696","citation_count":31,"is_preprint":false},{"pmid":"31511326","id":"PMC_31511326","title":"Ikzf1 regulates embryonic T lymphopoiesis via Ccr9 and Irf4 in zebrafish.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31511326","citation_count":31,"is_preprint":false},{"pmid":"21245044","id":"PMC_21245044","title":"Ikaros interacts with P-TEFb and cooperates with GATA-1 to enhance transcription elongation.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21245044","citation_count":29,"is_preprint":false},{"pmid":"38255194","id":"PMC_38255194","title":"IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/38255194","citation_count":27,"is_preprint":false},{"pmid":"33691560","id":"PMC_33691560","title":"Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology.","date":"2021","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33691560","citation_count":27,"is_preprint":false},{"pmid":"24697319","id":"PMC_24697319","title":"Gene-gene interactions of IRF5, STAT4, IKZF1 and ETS1 in systemic lupus erythematosus.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24697319","citation_count":27,"is_preprint":false},{"pmid":"30635395","id":"PMC_30635395","title":"Lack of Ikaros Deregulates Inflammatory Gene Programs in T Cells.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30635395","citation_count":27,"is_preprint":false},{"pmid":"22782532","id":"PMC_22782532","title":"IKZF1: a critical role in the pathogenesis of systemic lupus erythematosus?","date":"2012","source":"Modern rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/22782532","citation_count":26,"is_preprint":false},{"pmid":"33081843","id":"PMC_33081843","title":"The specific distribution pattern of IKZF1 mutation in acute myeloid leukemia.","date":"2020","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33081843","citation_count":26,"is_preprint":false},{"pmid":"38182668","id":"PMC_38182668","title":"IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38182668","citation_count":25,"is_preprint":false},{"pmid":"32654692","id":"PMC_32654692","title":"IKAROS Family Zinc Finger 1-Associated Diseases in Primary Immunodeficiency Patients.","date":"2020","source":"Immunology and allergy clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/32654692","citation_count":25,"is_preprint":false},{"pmid":"33357426","id":"PMC_33357426","title":"Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33357426","citation_count":25,"is_preprint":false},{"pmid":"36537580","id":"PMC_36537580","title":"Ikaros family proteins redundantly regulate temporal patterning in the developing mouse retina.","date":"2023","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36537580","citation_count":25,"is_preprint":false},{"pmid":"29496670","id":"PMC_29496670","title":"IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation.","date":"2018","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29496670","citation_count":25,"is_preprint":false},{"pmid":"30420689","id":"PMC_30420689","title":"Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30420689","citation_count":25,"is_preprint":false},{"pmid":"38537633","id":"PMC_38537633","title":"A noncoding regulatory variant in IKZF1 increases acute lymphoblastic leukemia risk in Hispanic/Latino children.","date":"2024","source":"Cell genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38537633","citation_count":24,"is_preprint":false},{"pmid":"36702234","id":"PMC_36702234","title":"Ikzf1 as a novel regulator of microglial homeostasis in inflammation and neurodegeneration.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36702234","citation_count":24,"is_preprint":false},{"pmid":"26841869","id":"PMC_26841869","title":"Ikaros Is a Negative Regulator of B1 Cell Development and Function.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26841869","citation_count":24,"is_preprint":false},{"pmid":"30352248","id":"PMC_30352248","title":"Multiple functions of Ikaros in hematological malignancies, solid tumor and autoimmune diseases.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30352248","citation_count":22,"is_preprint":false},{"pmid":"26049627","id":"PMC_26049627","title":"IKAROS: a multifunctional regulator of the polymerase II transcription cycle.","date":"2015","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/26049627","citation_count":22,"is_preprint":false},{"pmid":"24692537","id":"PMC_24692537","title":"Transcription factor Ikaros represses protein phosphatase 2A (PP2A) expression through an intronic binding site.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24692537","citation_count":21,"is_preprint":false},{"pmid":"12444977","id":"PMC_12444977","title":"The Ikaros family protein Eos associates with C-terminal-binding protein corepressors.","date":"2002","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12444977","citation_count":21,"is_preprint":false},{"pmid":"33284947","id":"PMC_33284947","title":"Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33284947","citation_count":21,"is_preprint":false},{"pmid":"18032925","id":"PMC_18032925","title":"Notch and Ikaros: not only converging players in T cell leukemia.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18032925","citation_count":20,"is_preprint":false},{"pmid":"11063871","id":"PMC_11063871","title":"Ikaros expression in human hematopoietic lineages.","date":"2000","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11063871","citation_count":19,"is_preprint":false},{"pmid":"14596876","id":"PMC_14596876","title":"Upstream of Ikaros.","date":"2003","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14596876","citation_count":18,"is_preprint":false},{"pmid":"28670491","id":"PMC_28670491","title":"The transcription factor Ikaros inhibits cell proliferation by downregulating ANXA4 expression in hepatocellular carcinoma.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28670491","citation_count":18,"is_preprint":false},{"pmid":"34265590","id":"PMC_34265590","title":"Inborn errors of IKAROS and AIOLOS.","date":"2021","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34265590","citation_count":17,"is_preprint":false},{"pmid":"31333801","id":"PMC_31333801","title":"RAG1 high expression associated with IKZF1 dysfunction in adult B-cell acute lymphoblastic leukemia.","date":"2019","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31333801","citation_count":17,"is_preprint":false},{"pmid":"39486420","id":"PMC_39486420","title":"Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39486420","citation_count":16,"is_preprint":false},{"pmid":"30312729","id":"PMC_30312729","title":"Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30312729","citation_count":16,"is_preprint":false},{"pmid":"23732910","id":"PMC_23732910","title":"Direct protein interactions are responsible for Ikaros-GATA and Ikaros-Cdk9 cooperativeness in hematopoietic cells.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23732910","citation_count":16,"is_preprint":false},{"pmid":"38885295","id":"PMC_38885295","title":"IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38885295","citation_count":15,"is_preprint":false},{"pmid":"34354970","id":"PMC_34354970","title":"Ikaros-Associated Diseases: From Mice to Humans and Back Again.","date":"2021","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34354970","citation_count":15,"is_preprint":false},{"pmid":"23580163","id":"PMC_23580163","title":"Ectopic Ikaros expression positively correlates with lung cancer progression.","date":"2013","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/23580163","citation_count":15,"is_preprint":false},{"pmid":"33180866","id":"PMC_33180866","title":"Ikaros antagonizes DNA binding by STAT5 in pre-B cells.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33180866","citation_count":14,"is_preprint":false},{"pmid":"25012940","id":"PMC_25012940","title":"IKZF1 rs4132601 polymorphism and acute lymphoblastic leukemia susceptibility: a meta-analysis.","date":"2015","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/25012940","citation_count":14,"is_preprint":false},{"pmid":"36997950","id":"PMC_36997950","title":"The clinical impact of IKZF1 mutation in acute myeloid leukemia.","date":"2023","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36997950","citation_count":14,"is_preprint":false},{"pmid":"30001316","id":"PMC_30001316","title":"Ikaros cooperates with Notch activation and antagonizes TGFβ signaling to promote pDC development.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30001316","citation_count":14,"is_preprint":false},{"pmid":"39112517","id":"PMC_39112517","title":"CCL2 mediated IKZF1 expression promotes M2 polarization of glioma-associated macrophages through CD84-SHP2 pathway.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39112517","citation_count":13,"is_preprint":false},{"pmid":"40268897","id":"PMC_40268897","title":"IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40268897","citation_count":13,"is_preprint":false},{"pmid":"26912004","id":"PMC_26912004","title":"Protein signaling and regulation of gene transcription in leukemia: role of the Casein Kinase II-Ikaros axis.","date":"2016","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/26912004","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42929,"output_tokens":8128,"usd":0.125354,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17786,"output_tokens":4679,"usd":0.102953,"stage2_stop_reason":"end_turn"},"total_usd":0.228307,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"Lenalidomide causes selective ubiquitination and proteasomal degradation of IKZF1 (and IKZF3) via the CRBN-CRL4 E3 ubiquitin ligase complex. A single amino acid substitution in IKZF3 conferred resistance to lenalidomide-induced degradation, confirming the mechanism. Lenalidomide-induced IL-2 production in T cells was also attributed to depletion of IKZF1/IKZF3.\",\n      \"method\": \"Quantitative proteomics, ubiquitination assays, rescue with amino acid substitution mutant, genetic knockdown\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — quantitative proteomics plus mutagenesis rescue, replicated independently in same year by Lu et al. (PMID:24292623)\",\n      \"pmids\": [\"24292625\", \"24292623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lenalidomide-bound cereblon E3 ubiquitin ligase acquires the ability to target IKZF1 and IKZF3 for proteasomal degradation. Loss of IKZF1 and IKZF3 is both necessary and sufficient for lenalidomide's therapeutic effect in myeloma cell lines.\",\n      \"method\": \"Biochemical binding assays, genetic loss-of-function in myeloma cell lines, proteasomal degradation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — necessity and sufficiency demonstrated with genetic approaches, independently replicated (PMID:24292625)\",\n      \"pmids\": [\"24292623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"LyF-1 (the lymphocyte-specific DNA-binding protein that activates TdT, lambda5, VpreB, and lck promoters) is encoded by specific alternatively spliced mRNAs from the Ikaros gene. Only isoforms containing the N-terminal zinc finger domain are necessary and sufficient for TdT promoter binding; at least six distinct mRNA isoforms arise from alternative splicing with differing DNA-binding specificities.\",\n      \"method\": \"Protein purification, partial amino acid sequencing, recombinant protein expression in E. coli, antibody blocking of DNA-binding activity, RT-PCR isoform analysis, gel-shift assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution with recombinant protein plus antibody blocking plus isoform mutagenesis, foundational identity paper\",\n      \"pmids\": [\"7935426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"LyF-1 (IKZF1) is a ~50 kDa sequence-specific DNA-binding protein that interacts with the consensus sequence PyPyTGGGAGPu in the TdT promoter (required for lymphocyte transcription), the immunoglobulin mu enhancer microB element, and promoters of lambda5, VpreB, and lck, identifying it as a general transcriptional activator for lymphocyte-specific genes.\",\n      \"method\": \"Protein purification, gel-shift (EMSA), transient transfection, promoter mutational analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — purified protein, in vitro DNA-binding assays, functional promoter analysis\",\n      \"pmids\": [\"1922043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Ikaros acts as a tumor suppressor and regulator of T cell proliferation thresholds; heterozygous mutation in the DNA-binding domain causes T cell hyperproliferation, autoproliferative peripheral T cells, and rapid T cell leukemia/lymphoma with 100% penetrance via clonal expansion and loss of the wild-type allele.\",\n      \"method\": \"Mouse genetics (heterozygous knock-in of DNA-binding domain mutation), flow cytometry, clonal analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo dominant-negative genetic model with clear phenotypic readout, foundational study\",\n      \"pmids\": [\"7585946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IKZF1 is SUMOylated in vivo at two identified sites; simultaneous modification of both SUMOylation sites abolishes Ikaros repression function by disrupting both HDAC-dependent and HDAC-independent repression, without affecting nuclear localization to pericentromeric heterochromatin.\",\n      \"method\": \"In vivo SUMOylation assays, site-directed mutagenesis of SUMOylation sites, HDAC activity assays, nuclear localization imaging\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis of specific SUMOylation sites with functional repression readout, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15767674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Ikaros interacts with protein phosphatase 1 (PP1) via a conserved RVXF motif in its C-terminus. PP1 dephosphorylates CK2-phosphorylated sites on Ikaros, stabilizing the protein and enabling pericentromeric heterochromatin (PC-HC) localization and DNA binding. Point mutations abolishing Ikaros-PP1 interaction decrease DNA binding, prevent PC-HC localization, and accelerate proteasomal degradation of Ikaros via the ubiquitin pathway.\",\n      \"method\": \"Co-immunoprecipitation, RVXF motif mutagenesis, subcellular localization imaging, DNA-binding assays, protein stability (half-life) assays, ubiquitin co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis of PP1-binding motif with multiple functional readouts (localization, DNA binding, stability), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"19282287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CK2 kinase phosphorylates Ikaros at four specific sites; phosphomimetic mutations at these CK2 sites inhibit Ikaros localization to pericentromeric heterochromatin, reduce DNA binding to target gene promoters (e.g., TdT), and promote proteasomal degradation of Ikaros. Phosphoresistant mutations at CK2 sites restore DNA binding, PC-HC localization, and prevent accelerated degradation.\",\n      \"method\": \"Ikaros phosphomimetic and phosphoresistant mutants, subcellular localization assays, ChIP, DNA-binding assays, protein stability assays\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phosphomimetic and phosphoresistant mutagenesis with multiple functional readouts, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21750978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ikaros and Aiolos bind directly to the c-Myc promoter in pre-B cells in vivo and suppress c-Myc expression. Downregulation of c-Myc is necessary for the growth-inhibitory effect of Ikaros/Aiolos, and precedes p27 induction and cyclin D3 downregulation.\",\n      \"method\": \"ChIP, siRNA knockdown, overexpression, cell proliferation assays, time-course expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates direct promoter occupancy, functional rescue/loss experiments, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"20566697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Ikaros forms a complex with Polycomb Repressive Complex 2 (PRC2) in CD4−CD8− thymocytes, enabling PRC2 binding to >500 developmentally regulated loci including haematopoietic stem cell and Notch pathway genes. Loss of Ikaros in these cells reduces H3K27 trimethylation and causes ectopic gene expression. Ikaros interaction with PRC2 is independent of the NuRD complex.\",\n      \"method\": \"Conditional genetic inactivation, ChIP-seq, co-immunoprecipitation, H3K27me3 assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus ChIP-seq plus genetic KO with epigenetic readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26549758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Upon T cell activation, Ikaros proteins localize to a higher-order chromatin structure at pericentromeric heterochromatin where they colocalize with components of the DNA replication machinery. T cells with reduced Ikaros activity show chromosome abnormalities when proliferating, implicating Ikaros in chromosome propagation during cell cycle.\",\n      \"method\": \"Immunofluorescence/nuclear localization imaging, chromosome analysis in proliferating T cells, TCR and IL-2 signaling assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment tied to chromosome phenotype in reduced-Ikaros T cells, single lab, two orthogonal methods\",\n      \"pmids\": [\"10204489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Endogenous Ikaros is recruited to the human beta-globin locus and targets HDAC1 and Mi-2 to gamma-globin promoters, contributing to gamma-globin gene silencing. Ikaros physically interacts with GATA-1 and enhances GATA-1 binding to regulatory regions, and their combined action impairs proximity between the locus control region and gamma-globin genes.\",\n      \"method\": \"ChIP, co-immunoprecipitation, reporter assays, chromosome conformation capture (3C)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP, Co-IP, and chromosome conformation capture in primary cells, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"19114560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Ikaros physically interacts with Cdk9 (a component of P-TEFb) via its N-terminal zinc finger domain and with GATA factors via its C-terminal zinc finger domain. These interactions promote transcription elongation of Ikaros target genes (including gamma-globin) by facilitating Cdk9 and GATA recruitment to promoters and conversion of RNA Pol II to the elongation-competent form. The oncogenic isoform Ik6 fails to interact with Cdk9 or GATA and perturbs Pol II elongation.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping/mutagenesis, ChIP, in vivo transcription elongation assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — domain mutagenesis plus ChIP plus functional transcription assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21245044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Direct protein-protein interactions between Ikaros C-terminal zinc fingers and GATA1/GATA2/GATA3 C-terminal zinc fingers, and between Ikaros N-terminal zinc fingers and the kinase/T-loop domain of Cdk9, are required for transcriptional activation of Ikaros target genes in hematopoietic cells. The Ik6 oncogenic isoform does not efficiently interact with Cdk9 or GATA proteins in vivo, perturbing P-TEFb recruitment and transcription elongation.\",\n      \"method\": \"Co-immunoprecipitation, domain deletion/mutagenesis, ChIP, transcriptional reporter assays in COS-7 and primary hematopoietic cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — detailed domain mutagenesis plus Co-IP plus ChIP, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23732910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Reintroduction of Ikaros into Ikaros-null T leukemia cells causes G0/G1 cell cycle arrest with upregulation of p27kip1, induction of T cell differentiation markers, and global and locus-specific increase in histone H3 acetylation, demonstrating Ikaros has tumor suppressor properties in T cells.\",\n      \"method\": \"Ikaros overexpression in leukemia cell line, flow cytometry (cell cycle), Western blot, immunofluorescence, histone acetylation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in defined cell line with multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"15713624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Ikaros directly occupies the tbx21 (T-bet) promoter in Th2 cells to repress T-bet expression and prevent IFNγ production. Loss of Ikaros DNA-binding in Th2 conditions leads to T-bet expression and IFNγ production. Ikaros is also required for epigenetic imprinting of the ifng locus during Th2 polarization.\",\n      \"method\": \"ChIP (endogenous Ikaros occupancy), dominant-negative Ikaros inhibition, cytokine production assays, in vivo parasite model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus dominant-negative functional experiment, single lab, two methods\",\n      \"pmids\": [\"19923223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Disruption of Ikaros in chicken DT40 B cells causes B cell receptor (BCR) signaling defects including reduced PLCγ2 phosphorylation, impaired intracellular calcium mobilization, and hyperphosphorylation of Cbl following BCR activation. These defects are rescued by Ikaros reintroduction.\",\n      \"method\": \"Gene disruption in DT40 cells, Ikaros reintroduction, phosphorylation assays, calcium mobilization assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic KO with rescue, multiple signaling readouts, single lab\",\n      \"pmids\": [\"16482514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Ikaros overexpression decreases NOTCH-induced megakaryocytic specification and represses megakaryocytic genes including GATA-1. Combined loss of Ikzf1 and Gata1 produces synthetic lethality in vivo with expansion of megakaryocyte progenitors, demonstrating a functional interplay between Ikaros, GATA factors, and the NOTCH pathway in megakaryopoiesis.\",\n      \"method\": \"Overexpression, genetic knockout (single and double), in vivo mouse models, flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (synthetic lethality), overexpression studies, single lab\",\n      \"pmids\": [\"23335373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In myeloid cells, IKZF1 regulates pyroptosis via canonical inflammasome signaling in a SIRT1-dependent manner. Ikaros negatively regulates SIRT1 through an AMPK-dependent pathway. Myeloid-specific Ikaros signaling augments hepatic pyroptosis and pro-inflammatory responses in vivo.\",\n      \"method\": \"Ikaros silencing/overexpression in BMM cultures, myeloid-specific Sirt1-KO mice, in vivo liver ischemia-reperfusion model, inflammasome signaling assays\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with mechanistic pathway readouts, single lab, multiple in vivo and in vitro models\",\n      \"pmids\": [\"34871625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Human Ikaros isoforms hIK-VI and hIK-H differ in DNA-binding affinity and subcellular localization: hIK-VI localizes exclusively to pericentromeric heterochromatin (PC-HC) while hIK-H shows dual centromeric and non-centromeric localization. Mutational analysis defined amino acids responsible for hIK-H's distinct DNA binding and localization. Co-expression of hIK-H with hIK-VI alters the DNA-binding specificity of Ikaros complexes toward PC-HC sequences.\",\n      \"method\": \"Isoform expression, mutational analysis, subcellular localization imaging, DNA-binding assays (EMSA), ChIP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus localization plus DNA-binding experiments, single lab\",\n      \"pmids\": [\"17135265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ikaros antagonizes STAT5 DNA binding in pre-B cells by competing for overlapping GGAA binding motifs at >60% of STAT5 target genomic regions, causing widespread loss of STAT5 chromatin binding within two hours of Ikaros induction. Ikaros does not alter STAT5 protein levels or phosphorylation, nor does it physically associate with STAT5.\",\n      \"method\": \"ChIP-seq (genomic distribution of Ikaros and STAT5), inducible Ikaros expression system, Western blot, co-immunoprecipitation (negative for STAT5 interaction)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus inducible system showing rapid displacement, single lab, two orthogonal methods\",\n      \"pmids\": [\"33180866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IKAROS assembles lineage-specific chromatin organization at multiple scales in B cell precursors, including interactions across megabase distances that override CTCF-imposed boundaries and build lineage-specific regulatory units. IKAROS-bound enhancers drive these long-range interactions. Gain-of-function in epithelial cells confirms IKAROS' direct ability to reconfigure chromatin architecture. IKAROS is also required for Igκ locus compaction in lymphocytes.\",\n      \"method\": \"Loss-of-function (conditional KO in B cell precursors), gain-of-function (ectopic expression in epithelial cells), Hi-C/chromatin conformation capture, ChIP-seq\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — complementary LOF and GOF genetics plus Hi-C chromatin architecture, multiple cell types, rigorous controls\",\n      \"pmids\": [\"37995656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Ikaros binds to a variant site in the first intron of PP2A and represses PP2A (PP2Ac) expression at the mRNA and protein level. This repression is at least partially dependent on recruitment of HDAC1 to the intronic binding site. Silencing of Ikaros enhances PP2A expression.\",\n      \"method\": \"ChIP, siRNA knockdown, overexpression, luciferase reporter assays, Western blot, RT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP showing occupancy, siRNA bidirectional regulation, single lab, multiple methods\",\n      \"pmids\": [\"24692537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Ikaros controls B cell receptor anergy by regulating anergy-associated genes including Zfp318 (which promotes IgD expression in anergic B cells). In Ikaros-deficient mature B cells, TLR-MyD88-NF-κB signaling is hyperactive due to failure to upregulate feedback inhibitors. Loss of MyD88 in Ikaros-deficient B cells prevents systemic autoimmunity.\",\n      \"method\": \"Conditional KO in mature B cells, genetic epistasis (MyD88 deletion), gene expression analysis, BCR/TLR signaling assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO plus epistasis rescue experiment, multiple signaling readouts\",\n      \"pmids\": [\"31591571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IKZF1 directly regulates CD34+ cell fate by being degraded via CRBN E3 ligase upon IMiD treatment, reducing IKZF1-dependent PU.1 transcription factor expression. ChIP shows IKZF1 directly binds the PU.1 promoter. CRBN knockdown reverses IMiD-induced IKZF1 downregulation. An IKZF1-Q146H mutation blocks CRBN binding and prevents IKZF1 ubiquitination.\",\n      \"method\": \"ChIP, thalidomide analog bead pull-down, CRBN knockdown (shRNA), IKZF1 Q146H mutant overexpression, colony-formation assays, xenograft model\",\n      \"journal\": \"Blood advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP plus pull-down plus mutagenesis plus knockdown rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"29496670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IKZF1 directly represses Cish (a negative regulator of IL-15 receptor signaling) in NK cells; Ikzf1-null NK cells have impaired IL-15 receptor signaling and increased BIM-mediated apoptosis. IKZF1 and IKZF3 directly bind AP-1 family members (Jun/Fos); deletion of both Ikzf1 and Ikzf3 in NK cells further reduces Jun/Fos expression and causes complete loss of peripheral NK cells.\",\n      \"method\": \"Conditional genetic inactivation (Ikzf1 KO, Ikzf1/Ikzf3 double KO, Ikzf1/Bcl2l11 co-deletion), ChIP-seq (direct AP-1 binding), cytokine signaling assays, flow cytometry\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq plus multiple genetic models with epistasis, replicated across conditions\",\n      \"pmids\": [\"38182668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IKZF1 drives T cell exhaustion via epigenetic modulation; degradation of IKZF1 by iberdomide prevents exhaustion by blocking chromatin remodeling at T cell effector enhancers and preserving binding of AP-1, NF-κB, and NFAT transcription factors.\",\n      \"method\": \"Antigen-specific T cell exhaustion assay, epigenetic screen, ATAC-seq/chromatin accessibility, iberdomide treatment, transcription factor occupancy assays\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin accessibility assays plus TF occupancy analysis with IKZF1 degrader, single lab, multiple methods\",\n      \"pmids\": [\"39486420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In zebrafish, Ikzf1 directly regulates Ccr9a and Irf4a expression, which are required for thymic migration and T cell differentiation of hematopoietic stem/progenitor cells respectively. Restoration of ccr9a in ikzf1 mutants rescues thymic homing but not T cell differentiation; additional irf4a restoration rescues differentiation.\",\n      \"method\": \"Zebrafish genetic ablation (ikzf1 mutant), genetic rescue (ccr9a and irf4a reintroduction), ChIP/direct target validation, flow cytometry of thymic populations\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in zebrafish ortholog with direct target validation, single lab\",\n      \"pmids\": [\"31511326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Germline IKZF1 variants affecting the C-terminal dimerization domain disrupt IKZF1 homo- and heterodimerization (completely or partially) without affecting wild-type allele function. These dimerization-defective mutants alter IKZF1 sumoylation, protein stability, and recruitment of the NuRD complex, contrasting with N-terminal DNA-binding defect mutants, which do not affect these mechanisms.\",\n      \"method\": \"Dimerization assays, sumoylation assays, protein stability assays, NuRD complex co-immunoprecipitation, patient germline variant characterization\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical assays on patient variants, single lab, multiple methods\",\n      \"pmids\": [\"32845957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ikaros-1 is expressed at the boundary of the striatal germinal zone/mantle zone during neurogenesis, where it induces cell cycle arrest of neural progenitors by upregulating p21Cip1/Waf1 and promotes differentiation of enkephalin-positive neurons. Ikaros-1 acts downstream of Dlx1/2 transcription factors in the striatum.\",\n      \"method\": \"Ikaros-KO mouse analysis, overexpression in primary striatal cultures, Dlx1/2 double-KO analysis, immunohistochemistry\",\n      \"journal\": \"The Journal of comparative neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus overexpression plus epistasis (Dlx1/2 double KO), single lab\",\n      \"pmids\": [\"19950118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A germline IKZF1 variant in IgG4-RD patients increases binding to the FYN promoter, resulting in higher FYN transcription in T cells. Elevated FYN stabilizes JunB and biases T cells toward Th2 polarization. This mechanistic chain accounts for atopic/autoimmune manifestations linked to IKZF1 risk variants.\",\n      \"method\": \"Functional characterization of patient germline variant, promoter binding assay (increased FYN binding), T cell differentiation assays, T cell receptor transduction assay\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding assay plus functional T cell differentiation, single lab/family study\",\n      \"pmids\": [\"38885295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IKAROS regulates surface expression of CD19 and CD22 in a dose-dependent and reversible manner in B-ALL cells. IKAROSlow B-ALL cells undergo epigenetic and transcriptional changes reducing B-cell identity, which leads to reduced CD19 and CD22 surface expression and resistance to CAR T cell therapies.\",\n      \"method\": \"Single-cell analysis of 61 patient samples, IKAROS dose-dependent overexpression/knockdown experiments, epigenetic assays (ATAC-seq), antigen expression assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dose-dependent manipulation plus epigenetic profiling, single lab, multiple methods\",\n      \"pmids\": [\"40268897\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IKZF1/IKAROS is a zinc finger transcription factor that binds GGAA-containing DNA motifs (via N-terminal zinc fingers) and dimerizes (via C-terminal zinc fingers), directly activating or repressing target genes in hematopoietic cells; it recruits chromatin-remodeling complexes (NuRD/HDAC, PRC2) and the transcription elongation factor P-TEFb/Cdk9 to regulatory elements, controls pericentromeric heterochromatin localization, interacts with GATA factors, antagonizes STAT5 chromatin binding, assembles lineage-specific 3D genome architecture, and is subject to post-translational regulation by CK2 phosphorylation (which impairs DNA binding and promotes degradation), PP1-mediated dephosphorylation (which stabilizes the protein), and SUMOylation (which blocks repression); additionally, lenalidomide and related IMiD drugs redirect the CRBN-CRL4 E3 ubiquitin ligase to ubiquitinate and proteasomally degrade IKZF1, a mechanism that underlies both the anti-myeloma activity of these drugs and their effects on T cells and innate lymphoid cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IKZF1/IKAROS is a lymphocyte-restricted zinc finger transcription factor that programs hematopoietic gene expression by binding GGAA-containing DNA motifs and orchestrating both activation and repression of lineage-specific genes [#3, #2]. First identified as the DNA-binding protein LyF-1 that engages the TdT, mu enhancer, lambda5, VpreB, and lck promoters, its sequence specificity and dimerization properties are partitioned across distinct zinc finger domains and tuned by extensive alternative splicing into isoforms with differing DNA-binding affinity and pericentromeric heterochromatin localization [#3, #2, #19]. IKAROS executes transcriptional control through partner recruitment: its N-terminal zinc fingers engage Cdk9/P-TEFb to drive RNA Pol II elongation while its C-terminal fingers bind GATA1/2/3, and it additionally recruits HDAC1/Mi-2 (NuRD), PRC2, and assembles long-range, lineage-specific chromatin architecture that overrides CTCF boundaries [#12, #13, #11, #9, #21]. It directly represses growth and identity genes including c-Myc, T-bet, PP2A, Cish, and the megakaryocytic program, and antagonizes STAT5 by competing for overlapping GGAA sites, thereby setting proliferation thresholds and enforcing lineage choice across B, T, NK, and myeloid cells [#8, #15, #22, #25, #20, #17]. Consistent with this role, IKAROS is a tumor suppressor whose loss or DNA-binding-domain mutation drives T cell hyperproliferation and leukemia [#4, #14]. IKAROS activity is set by post-translational regulation: CK2 phosphorylation impairs DNA binding and promotes degradation, PP1-mediated dephosphorylation stabilizes the protein and enables heterochromatin localization, and SUMOylation blocks its repressive function [#7, #6, #5]. Lenalidomide and related IMiDs redirect the CRBN-CRL4 E3 ubiquitin ligase to ubiquitinate and degrade IKZF1, the basis of their anti-myeloma activity and of their immunomodulatory effects, with a Q146H substitution conferring degradation resistance [#1, #0, #24]. Germline IKZF1 variants disrupting either dimerization or DNA binding alter NuRD recruitment, stability, and downstream signaling, underlying immune dysregulation phenotypes [#28, #30].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established the molecular identity of IKAROS as a sequence-specific transcriptional activator, answering what protein controls lymphocyte-specific promoters.\",\n      \"evidence\": \"Protein purification and EMSA on the TdT, mu enhancer, lambda5, VpreB, and lck promoters\",\n      \"pmids\": [\"1922043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gene/cDNA identity not yet established at this stage\", \"No in vivo loss-of-function\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Linked LyF-1 DNA-binding activity to the Ikaros gene and showed alternative splicing generates isoforms with distinct DNA-binding specificities, explaining functional diversity from a single locus.\",\n      \"evidence\": \"Recombinant protein expression, antibody blocking, RT-PCR isoform analysis, gel-shift\",\n      \"pmids\": [\"7935426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of each isoform in vivo unresolved\", \"Partner proteins not yet identified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined IKAROS as a tumor suppressor that sets T cell proliferation thresholds, answering whether IKAROS dysfunction is oncogenic.\",\n      \"evidence\": \"Mouse heterozygous knock-in of a DNA-binding domain mutation with clonal analysis\",\n      \"pmids\": [\"7585946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes mediating tumor suppression not defined here\", \"Mechanism of wild-type allele loss unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Connected IKAROS to higher-order chromatin and chromosome propagation, addressing where in the nucleus IKAROS acts upon T cell activation.\",\n      \"evidence\": \"Immunofluorescence localization to pericentromeric heterochromatin and chromosome analysis in proliferating T cells\",\n      \"pmids\": [\"10204489\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of heterochromatin targeting not defined\", \"Causal link between localization and chromosome stability correlative\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified SUMOylation as a switch controlling IKAROS repression, answering how repressive activity is post-translationally toggled.\",\n      \"evidence\": \"In vivo SUMOylation assays, site mutagenesis, HDAC and localization readouts\",\n      \"pmids\": [\"15767674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SUMO ligase/protease responsible not identified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed IKAROS controls BCR signaling and that isoforms differ in DNA-binding and subcellular targeting, refining how IKAROS output is diversified.\",\n      \"evidence\": \"DT40 gene disruption with rescue plus signaling assays; isoform mutational and localization analysis\",\n      \"pmids\": [\"16482514\", \"17135265\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in BCR pathway not mapped\", \"Isoform stoichiometry in primary cells unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined IKAROS as a recruiter of HDAC1/Mi-2 and a GATA-1 partner that reshapes locus architecture, answering how it silences specific genes.\",\n      \"evidence\": \"ChIP, Co-IP, reporter assays, and 3C at the human beta-globin locus\",\n      \"pmids\": [\"19114560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality beyond globin locus not addressed here\", \"Order of complex assembly unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed IKAROS directly represses c-Myc to inhibit pre-B cell growth, providing a target-level mechanism for its anti-proliferative role.\",\n      \"evidence\": \"ChIP, siRNA/overexpression, proliferation and time-course expression assays\",\n      \"pmids\": [\"20566697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactor requirement at c-Myc promoter not defined\", \"Cell-type generality untested here\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established the kinase/phosphatase logic and the P-TEFb/GATA recruitment mechanism, answering how IKAROS activity and activating output are controlled.\",\n      \"evidence\": \"CK2 phosphomimetic/phosphoresistant mutants and Cdk9/GATA domain-mapping with ChIP and elongation assays\",\n      \"pmids\": [\"21750978\", \"21245044\", \"19282287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo phosphorylation dynamics during development unclear\", \"Single-lab mechanistic studies\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed the IMiD/CRBN degradation mechanism and resolved domain-specific partner contacts, transforming IKAROS into a druggable target and mapping its activation interface.\",\n      \"evidence\": \"Quantitative proteomics, ubiquitination assays, mutagenesis rescue in myeloma; domain mutagenesis with ChIP for GATA/Cdk9 contacts\",\n      \"pmids\": [\"24292625\", \"24292623\", \"23732910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of neosubstrate-determining residues incomplete\", \"Long-range chromatin consequences of degradation not addressed here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated IKAROS recruits PRC2 to deposit H3K27me3 at developmental loci, adding a Polycomb repression axis distinct from NuRD.\",\n      \"evidence\": \"Conditional KO, ChIP-seq, Co-IP, and H3K27me3 profiling in thymocytes\",\n      \"pmids\": [\"26549758\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Recruitment determinants for PRC2 vs NuRD selectivity unknown\", \"Direct vs indirect PRC2 contact not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed IKAROS antagonizes STAT5 by motif competition rather than protein interaction, clarifying a mechanism of signaling cross-regulation.\",\n      \"evidence\": \"ChIP-seq with inducible IKAROS, Western blot, and negative Co-IP in pre-B cells\",\n      \"pmids\": [\"33180866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences for B cell development not quantified here\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established IKAROS as a direct architect of lineage-specific 3D genome organization, answering how it imposes regulatory units genome-wide.\",\n      \"evidence\": \"Conditional KO, ectopic gain-of-function in epithelial cells, Hi-C and ChIP-seq\",\n      \"pmids\": [\"37995656\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of CTCF-boundary override not molecularly defined\", \"Cohesin/loop-extrusion interplay unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended IKAROS function to NK cell survival, T cell exhaustion, and AP-1 partnership, broadening its lineage roles and therapeutic relevance.\",\n      \"evidence\": \"Conditional/double-KO genetics with ChIP-seq (NK); ATAC-seq and TF occupancy with IKAROS degrader (T cell exhaustion); patient variant FYN promoter study\",\n      \"pmids\": [\"38182668\", \"39486420\", \"38885295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs cofactor-mediated AP-1 binding not fully resolved\", \"Generalizability of exhaustion findings beyond model systems untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked IKAROS dosage to B-cell identity antigen expression, explaining a mechanism of resistance to CD19/CD22-directed therapies.\",\n      \"evidence\": \"Single-cell analysis of patient samples plus dose-dependent manipulation with ATAC-seq\",\n      \"pmids\": [\"40268897\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect regulation of CD19/CD22 loci not separated\", \"Reversibility kinetics in vivo unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How IKAROS selects between its repressive (NuRD, PRC2, HDAC) and activating (P-TEFb, GATA) partner programs at a given locus, and how this is coordinated with its 3D architecture function, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of partner selection\", \"Recruitment hierarchy at individual loci undefined\", \"Integration of post-translational state with partner choice unmapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 2, 19, 20]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 8, 15, 12, 13]},\n      {\"term_id\": \"GO:0003700\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 6, 7, 19]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [10, 19, 21]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [9, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 12, 13, 8]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [9, 11, 21]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [23, 25, 15, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [17, 27, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 24, 28]}\n    ],\n    \"complexes\": [\"NuRD\", \"PRC2\"],\n    \"partners\": [\"GATA1\", \"GATA2\", \"GATA3\", \"CDK9\", \"HDAC1\", \"CRBN\", \"IKZF3\", \"PPP1CA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}